CAMP4 Therapeutic announced the initiation of toxicology studies conducted under Good Laboratory Practice standards for its lead product candidate, CMP-SYNGAP-01. These studies will support the Company’s planned submission of a clinical trial application, which could enable the initiation of a first-in-human Phase 1/2 clinical trial in SYNGAP1-related disorders as early as the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- Promising Prospects for CAMP4 Therapeutics: Buy Rating Affirmed Amid Advancements in CMP-SYNGAP-01 Program and Strong Investor Confidence
- Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
- Camp4 Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Camp4 Therapeutics price target lowered to $12 from $18 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today